COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Moritz Fürstenau; Petra Langerbeins; Nisha De Silva; Anna Maria Fink; Sandra Robrecht; Julia von Tresckow; Florian Simon; Karin Hohloch; Jolanda Droogendijk; Marjolein van der Klift; Ellen van der Spek; Thomas Illmer; Björn Schöttker; Kirsten Fischer; Clemens M Wendtner; Eugen Tausch; Stephan Stilgenbauer; Carsten U Niemann; Michael Gregor; Arnon P Kater; Michael Hallek; Barbara Eichhorst

doi:10.1038/s41375-020-0941-7

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Leukemia. 2020 Aug;34(8):2225-2229. doi: 10.1038/s41375-020-0941-7. Epub 2020 Jun 29.

Authors

Moritz Fürstenau^#¹, Petra Langerbeins^#², Nisha De Silva², Anna Maria Fink², Sandra Robrecht², Julia von Tresckow², Florian Simon², Karin Hohloch^{3

4}, Jolanda Droogendijk⁵, Marjolein van der Klift⁶, Ellen van der Spek⁷, Thomas Illmer⁸, Björn Schöttker⁹, Kirsten Fischer², Clemens M Wendtner¹⁰, Eugen Tausch¹¹, Stephan Stilgenbauer^{11

12}, Carsten U Niemann¹³, Michael Gregor¹⁴, Arnon P Kater¹⁵, Michael Hallek^{2

16}, Barbara Eichhorst²

Affiliations

¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany. [email protected].
² Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
³ Department of Internal Medicine, Hematology and Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland.
⁴ Department of Hematology and Oncology, University Hospital Göttingen, Göttingen, Germany.
⁵ Division of Hematology and Oncology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands.
⁶ Division of Hematology and Oncology, Amphia Ziekenhuis Breda, Breda, The Netherlands.
⁷ Department of Internal Medicine, Ziekenhuis Rijnstate, Arnhem, The Netherlands.
⁸ BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany.
⁹ Hämatologisch-onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany.
¹⁰ Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Munich Clinic Schwabing, Munich, Germany.
¹¹ Department of Internal Medicine III, University of Ulm, Ulm, Germany.
¹² Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
¹³ Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
¹⁴ Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
¹⁵ Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
¹⁶ Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.

^# Contributed equally.

No abstract available

Publication types

Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial

MeSH terms

Adenine / analogs & derivatives
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Betacoronavirus / isolation & purification*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
COVID-19
Coronavirus Infections / diagnosis
Coronavirus Infections / transmission*
Coronavirus Infections / virology
Female
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Leukemia, Lymphocytic, Chronic, B-Cell / virology
Male
Middle Aged
Pandemics
Piperidines
Pneumonia, Viral / diagnosis
Pneumonia, Viral / transmission*
Pneumonia, Viral / virology
Prognosis
Pyrazoles / administration & dosage
Pyrimidines / administration & dosage
Rituximab / administration & dosage
SARS-CoV-2
Sulfonamides / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Bridged Bicyclo Compounds, Heterocyclic
Piperidines
Pyrazoles
Pyrimidines
Sulfonamides
ibrutinib
Rituximab
Adenine
venetoclax
obinutuzumab

Associated data

ClinicalTrials.gov/NCT02950051